Clinical Trials Browser

Phase 1 × INDUSTRY × GRN163L peptide × Clear all

NCT00124189 2015-12-24

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell

NCT00732056 2015-12-24

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms